Objective Assessment of Rescue Medication Use and Inhalation Characteristics of COPD Patients Recorded by the Electronic ProAir Digihaler

Snyder, L.D.; Safioti, Guilherme; Reich, Michael; Neely, Megan L.; Lugogo, Njira L; Pleasants, Roy A.; Li, T.; Granovsky, Lena; DePietro, Michael

doi:10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4305

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inspiratory-capable digital inhalers add a physiological measure to the drug usage data around exacerbations. Similar to peak expiratory flow, peak inspiratory flow (PIF) is responsive to bronchodilators [ 81 ] and decreases during exacerbations [ 74 , 76 , 82 ]. Air trapping and airflow obstruction are important mechanisms for reducing PIF [ 83 , 84 ].…”

Section: Methodsmentioning

confidence: 99%

“…A study of the ProAir Digihaler ® in 336 patients with COPD, of whom about one-third ( n = 98) reported an exacerbation, found that PIF had not returned to baseline by 14 days, similar to expiratory flow patterns reported post-exacerbation [ 85 ]. By using machine learning for both trials, increased SABA use was the strongest predictor of an impending exacerbation in asthma, while in COPD, inspiratory flows were most important [ 76 , 77 ]. This has important implications when considering the role of digital inhalers, as inhalers that measure PIF could play a key role in asthma management by predicting risk of impending exacerbation through a reduction in PIF and inhalation volume or by recording more frequent SABA use.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

et al. 2021

View full text Add to dashboard Cite

Impressive advances in inhalation therapy for patients with asthma and chronic obstructive pulmonary disease (COPD) have occurred in recent years. However, important gaps in care remain, particularly relating to poor adherence to inhaled therapies. Digital inhaler health platforms which incorporate digital inhalers to monitor time and date of dosing are an effective disease and medication management tool, promoting collaborative care between clinicians and patients, and providing more in-depth understanding of actual inhaler use. With advances in technology, nearly all inhalers can be digitalized with add-on or embedded sensors to record and transmit data quantitating inhaler actuations, and some have additional capabilities to evaluate inhaler technique. In addition to providing an objective and readily available measure of adherence, they allow patients to interact with the device directly or through their self-management smartphone application such as via alerts and recording of health status. Clinicians can access these data remotely and

show abstract